Resveratrol and Alzheimer’s disease: message in a bottle on red wine and cognition
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Cognitive impairment is the final outcome of a complex network of molecular mechanisms ultimately leading to dementia. Despite major efforts aimed at unraveling the molecular determinants of dementia of Alzheimer type (DAT), effective disease-modifying approaches are still missing. An interesting and still largely unexplored avenue is offered by nutraceutical intervention. For instance, robust epidemiological data have suggested that moderate intake of red wine may protect against several age-related pathological conditions (i.e., cardiovascular diseases, diabetes, and cancer) as well as DAT-related cognitive decline. Wine is highly enriched in many polyphenols, including resveratrol. Resveratrol is a well recognized antioxidant which may modulate metal ion deregulation outcomes as well as main features of the Alzheimer's disease (AD) brain. The review will discuss the potentiality of resveratrol as a neuroprotectant in dementia in relation to the oxidative stress produced by amyloid and metal dysmetabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982 · cited 3×
“Frontiers in Aging Neuroscience www.frontiersin.org May 2014 | Volume 6 | Article 95 | 1 A recent review on aging determinants has proposed nine hallmarks for the process (López-Otín et al., 2013).”
BackgroundLagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057 · cited 1×
“Resveratrol has beneficial cardiovascular effects (Siemann and Creasy, 1992) throughout a great variety of molecular mechanisms (Howitz et al., 2003; Baur and Sinclair, 2006; Lagouge et al., 2006; Park et al., 2012).”
BackgroundSmall molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796 · cited 1×
“Resveratrol has beneficial cardiovascular effects (Siemann and Creasy, 1992) throughout a great variety of molecular mechanisms (Howitz et al., 2003; Baur and Sinclair, 2006; Lagouge et al., 2006; Park et al., 2012).”
BackgroundNLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 1×
“Pharmacological and genetic manipulations aimed at reducing brain inflammation appear to be effective in slowing/modifying the disease progression in AD animal models (Heneka et al., 2013; Giuliani et al., 2014).”
BackgroundMitochondria as sensors and regulators of calcium signalling
Rizzuto, R., De Stefani, D., Raffaello, A., & Mammucari, C. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3412 · Cited by 1,781 · cited 2×
“…the brain, metal ions are involved in many essential processes such as intracellular signaling, modulation of cellular redox and metabolic states, enzymatic activities and channels functioning (Billard, 2006; Sensi et al., 2009; Rizzuto et al., 2012; Sekler and Silverman, 2012; Gaier et al., 2013).”
BackgroundPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Gomes, A. P., Price, N. L., Ling, A. J. Y., Moslehi, J. J., Montgomery, M. K., Rajman, L., White, J. P., Teodoro, J. S., Wrann, C. D., Hubbard, B. P., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.037 · Cited by 1,482
Kim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., Delalle, I., Baur, J. A., Sui, G., Armour, S. M., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601758 · Cited by 1,074 · cited 1×
“In addition, the compound can reduce phospho-tau toxicity (induced by cyclin-dependent kinase 5-p25 dependent tau phosphorylation) by favoring the deacetylation of peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (PGC1α) and p53 (Kim et al., 2007).”
BackgroundNeurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
Mucke, L., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006338 · Cited by 1,000 · cited 2×
“Amyloid has been therefore the major target for therapeutic intervention (Hardy and Higgins, 1992; Mucke and Selkoe, 2012).”
BackgroundInfluentialAcetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy
Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., Huang, E. J., Shen, Y., Masliah, E., Mukherjee, C., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.044 · Cited by 949
Zinc in the physiology and pathology of the CNS
Sensi, S. L., Paoletti, P., Bush, A. I., & Sekler, I. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2734 · Cited by 759
Concentration of the Phytoalexin Resveratrol in Wine
Siemann, E. H., & Creasy, L. L. (1992) · American Journal of Enology and Viticulture · doi:10.5344/ajev.1992.43.1.49 · Cited by 719
Halagappa, V. K. M., Guo, Z., Pearson, M., Matsuoka, Y., Cutler, R. G., LaFerla, F. M., & Mattson, M. P. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.019 · Cited by 580 · cited 1×
“Fasting has been observed to promote beneficial effects on preclinical models of AD and aging not only by extending lifespan but also by ameliorating cognitive performances (Halagappa et al., 2007).”
BackgroundThe amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
McGeer, P. L., & McGeer, E. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1177-7 · Cited by 467 · cited 1×
“(McGeer and McGeer, 2013).”
Deciphering the mechanism underlying late-onset Alzheimer disease
Krstic, D., & Knuesel, I. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.236 · Cited by 457
Alzheimer's disease, metal ions and metal homeostatic therapy
Zatta, P., Drago, D., Bolognin, S., & Sensi, S. L. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.05.002 · Cited by 369 · cited 1×
“…cross-linker between tau phospho-sites, to “freeze” Aβ in its toxic oligomeric state, and to induce exposure of Aβ hydrophobic clusters aggregates, thereby boosting toxic properties of these misfolded proteins (Zatta et al., 2009; Bolognin et al., 2011; Chen et al., 2011; Granzotto et al., 2011).”
BackgroundSelf-citationSerum Brain-Derived Neurotrophic Factor and the Risk for Dementia: The Framingham Heart Study
Weinstein, G., Beiser, A. S., Choi, S. H., Preis, S. R., Chen, T. C., Vorgas, D., Au, R., Pikula, A., Wolf, P. A., DeStefano, A. L., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4781 · Cited by 289 · cited 1×
“Caloric restriction can in fact promote release of brain-derived neurotrophic factor (BDNF), a neurotrophin critically involved in counteracting cognitive decline (Weinstein et al., 2014).”
BackgroundThe role of metallobiology and amyloid-β peptides in Alzheimer's disease
Roberts, B. R., Ryan, T. M., Bush, A. I., Masters, C. L., & Duce, J. A. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07500.x · Cited by 266
Metal-associated amyloid-β species in Alzheimer's disease
Pithadia, A. S., & Lim, M. H. (2012) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.01.016 · Cited by 259 · cited 1×
“Moreover, all these ions can promote ROS generation (Sayre et al., 2000; Granzotto and Zatta, 2011; Pithadia and Lim, 2012; Ayton et al., 2013).”
BackgroundCopper excess, zinc deficiency, and cognition loss in Alzheimer's disease
Brewer, G. J. (2012) · BioFactors · doi:10.1002/biof.1005 · Cited by 188
Cited by
Polyphenols from Food and Natural Products: Neuroprotection and Safety
Silva, R. F. M., & Pogačnik, L. (2020) · Antioxidants · doi:10.3390/antiox9010061 · Cited by 293
Western diet is associated with a smaller hippocampus: a longitudinal investigation
Jacka, F. N., Cherbuin, N., Anstey, K. J., Sachdev, P., & Butterworth, P. (2015) · BMC Medicine · doi:10.1186/s12916-015-0461-x · Cited by 293
Effect of nutrition on neurodegenerative diseases. A systematic review
Bianchi, V. E., Herrera, P. F., & Laura, R. (2021) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1681088 · Cited by 249
“resents one component of the beneficial effect ofMedDiet due to resveratrol content [155,156] reducing the risk of”
BackgroundResveratrol Brain Delivery for Neurological Disorders Prevention and Treatment
Andrade, S., Ramalho, M. J., Pereira, M. D. C., & Loureiro, J. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01261 · Cited by 173
“Also, RES reduced the Aβ production (Pasinetti et al., 2015) through the activation of SIRT1 that activate the α-secretase (Donmez et al., 2010; Granzotto and Zatta, 2014) and the reduction of the activity of β-secretase (Jeon et al., 2007; Porquet et al., 2014).”
BackgroundInfluentialTiwari, S. K., Agarwal, S., Tripathi, A., & Chaturvedi, R. K. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9197-z · Cited by 114
Metadata
- Authors
- Granzotto, A., & Zatta, P.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2014-05-14
- Volume
- 6
- Pages
- 95-95
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2020060386
- Cited by
- 93
- References
- 20
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.